PHENOGENE-1a adjunctive treatment study in mild to moderate ALS

Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing PHENOGENE-1a plus riluzole with Placebo plus riluzole (2 arms). Primary endpoint: Absolute change in ALSFRS-R total score from baseline to Week 24. Planned start Jan 2026; status: authorised.